Charles River Laboratories (CRL) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| CHARLES RIVER LABORATORIE (NYSE: CRL) | Delayed: 331.83 -20.04 (5.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $351.87 | 52 Week High | $89.18 | |||
| Open | $349.90 | 52 Week Low | $65.70 | |||
| Day High | $354.99 | P/E | 154.34 | |||
| Day Low | $327.89 | EPS | $2.15 | |||
| Volume | 555,411 | |||||
